Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $5.5 million.

  • ImmunoTech's Liabilities and Shareholders Equity fell 5956.73% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year decrease of 6226.63%. This contributed to the annual value of $8.6 million for FY2024, which is 5558.54% down from last year.
  • ImmunoTech's Liabilities and Shareholders Equity amounted to $5.5 million in Q3 2025, which was down 5956.73% from $4.1 million recorded in Q2 2025.
  • ImmunoTech's 5-year Liabilities and Shareholders Equity high stood at $33.6 million for Q2 2023, and its period low was $4.1 million during Q2 2025.
  • Its 3-year average for Liabilities and Shareholders Equity is $15.1 million, with a median of $14.7 million in 2024.
  • As far as peak fluctuations go, ImmunoTech's Liabilities and Shareholders Equity plummeted by 5122.93% in 2024, and later tumbled by 7372.57% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Liabilities and Shareholders Equity stood at $19.4 million in 2023, then tumbled by 55.59% to $8.6 million in 2024, then plummeted by 36.18% to $5.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $5.5 million for Q3 2025, versus $4.1 million for Q2 2025 and $6.2 million for Q1 2025.